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 ABSTRACT 
Induced production of reactive oxygen species (ROS) is a common attribute of most 
cancer cells. One strategy for cancer cells to maneuver the increased and potentially 
toxic levels of ROS is to induce the expression of cellular antioxidants and redox 
regulators, such as the thioredoxin (Trx) system. The Trx system consists of Trx and 
the NADPH-dependent thioredoxin reductase (TrxR protein/Txnrd1 gene). TrxR 
reduces Trx, which subsequently reduces disulfides in various proteins and supplies 
ribonucleotide reductase with electrons for DNA synthesis. Mammalian TrxRs have 
wide substrate specificity, also reducing other targets than Trx. Cytosolic Trx1 and 
TrxR1 are induced upon oxidative stress and both have proven to be overexpressed in 
many tumors. They are therefore proposed as potential targets for anticancer therapy. 
TrxR is a selenoprotein and contains selenium in the form of selenocysteine (Sec). 
The Sec residue is mostly de-protonated at physiological pH and is highly 
nucleophilic, thus being easily targeted by electrophilic drugs.  
 
The aim of this thesis was to address the role of TrxR1 as a potential drug target for 
anticancer therapy and evaluate its importance for side effects associated with the 
widely used anticancer drug cisplatin (cDDP).  
 
This thesis reports that RITA, a compound shown to induce p53 dependent cell-death 
by interacting and restoring p53 activity, caused inhibition of TrxR1. Cell culture 
experiments showed that RITA induced a 130 kDa covalently linked TrxR1-dimer, in 
a p53 dependent fashion. Furthermore, red wine, rich of polyphenols and flavonoids, 
was also shown to efficiently inhibit TrxR activity and to be highly toxic to various 
cancer cell lines.  
 
Transient TrxR1 knockdown in a lung carcinoma cell line lowered the TrxR activity 
by 90% and caused increased sensitivity towards menadione and 1-chloro-2,4-
dinitrobenzene. TrxR1 knockdown cells were, however, more resistant towards cDDP. 
Depleting the glutathione (GSH) levels in knockdown cells had no effect on cell 
growth, suggesting that the remaining TrxR activity still was enough to sustain Trx 
function. Recent experiments in mice showed that normal replication of hepatocytes 
required either one functional copy of the Txnrd1 gene or a functional GSH system, 
agreeing with the previous interpretation. 
 
cDDP treatment is associated with side effects such as ototoxicity and nephrotoxicity. 
cDDP inhibits TrxR1 and cDDP-derivatized enzyme species have previously been 
shown to gain a pro-oxidant role in the cells. Data on cDDP-triggered nephrotoxicity 
in mice presented herein suggest that the degree of kidney damage is influenced by 
the TrxR status in both liver and kidney. Decreased TrxR activity in liver was 
associated with more renal damage, while high TrxR expression in kidney correlated 
with increased kidney toxicity. Pharmacokinetic studies on cDDP and oxaliplatin 
(Oxa) in guinea pig, showed that the cochlear uptake of cDDP was significantly 
higher than for Oxa, thus explaining why Oxa only rarely causes ototoxicity. Using a 
cancer cell line it was also shown that cDDP, but not Oxa, induced cell death which 
was dependent on calcium and superoxide levels and caused TrxR inhibition.  
 
In summary, this thesis shows that TrxR1 is an anticancer drug target that can have an 
important impact on the outcome of chemotherapy and its associated side effects. 
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1 INTRODUCTION 
1.1 CANCER 
Cancer is an age-related disease and one of the dominant causes of death in high-
income countries. In 2009, 54,611 new cases of cancer were diagnosed in Sweden 
and the calculated risk of developing cancer at some point in life was about 30% 
[1]. Cancer is a collective name for multiple disorders. Each individual cancer or 
solid tumor is unique and consists of a heterogenic population of chronically 
proliferating cells. Cancer is a genetic disease and a series of mutations are often 
the underlying cause for disturbances in cell signaling pathways. During recent 
years the scientific research community has expanded our perspectives, looking 
beyond the tumor mass, realizing there is a complex interplay between the tumor 
cells and the tissues and molecules surrounding the tumor.  
 
Certain characteristics are however shared by most cancers, which have previously 
been extensively described by Hanahan and Weinberg [2,3]. The necessary and 
acquired capability for tumor development includes sustained proliferative 
signaling, evading growth suppressors, activating invasion and metastasis, 
enabling replicative immortality, inducing angiogenesis and resisting cell death. 
Extensive research over the past years has shown that perhaps two additional 
features should be added to the list, namely the capability to avoid immune 
destruction and cellular metabolism reprogramming. By up-regulating the 
glycolysis pathway, tumor cells have for instance adjusted to low oxygen levels, 
this is called the Warburg effect [4]. 
 
1.2 REDOX SIGNALING 
Oxygen plays an important role in energy metabolism and the formation of 
reactive oxygen species (ROS) is therefore a normal consequence of aerobic 
metabolism [5,6]. ROS are oxygen species that are in a more reactive state than 
molecular oxygen and encompasses a diverse range of molecular species, for 
example superoxide (O2•
-), hydrogen peroxide (H2O2), nitric oxide (NO), 
peroxynitrite (OONO-), hypochlorous acid (HOCl) and the hydroxyl radical (OH•). 
Each of these molecules has its own reaction preferences. ROS can be categorized 
as free radicals, possessing one or more unpaired electrons, or as non-radical ROS. 
Reactive nitrogen species (RNS) are many times also regarded separately. Excess 
levels of ROS can be dangerous to cells but at low and controlled levels they have 
important physiological functions.  
 
The major endogenous producers of cellular ROS are the mitochondria, which 
drive the synthesis of adenosine-5'-triphosphate (ATP) via the respiratory chain 
[7,8,9,10]. Superoxide is produced due to electron leakage, which occurs when 
electrons passing down the respiratory chain exit prematurely. The two main sites 
in the respiratory chain where this can happen are complex I (NADH 
dehydrogenase) and complex III (ubisemiquinone) [11,12]. There are also 
numerous other sources for ROS production in the mitochondria that are important 
and significantly affect the total ROS levels. Consequently, the mitochondria are 
also a central target for ROS toxicity and dedicated antioxidants systems therefore 
play a crucial role in protecting and sustaining mitochondrial functions. Other 
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cellular sources of ROS production include nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidases (Nox), xanthine oxidase, glucose oxidase, 
lipoxygenases, nitric oxide synthase (NOS), flavoprotein reductases and 
myeloperoxidase [8]. There are also several possible exogenous ROS sources such 
as UV-light, ionizing radiation and metabolism of different xenobiotics.  
 
ROS also function as cellular signaling molecules. Superoxide radicals and 
hydrogen peroxide can modify the activity of nuclear transcription factors such as 
nuclear factor kappa B (NF-κB) and activator protein-1 (AP-1) [13,14,15]. ROS 
can furthermore modulate the activity of protein tyrosine kinases and phosphatases. 
The production of hydrogen peroxide is for instance required for insulin and 
growth factor-induced tyrosine kinase signaling [16,17,18]. Growth factors will 
activate Nox enzymes, whose specific subcellular localization regulates specificity 
and selectivity in oxidant signaling [19,20]. Nox derived reactive oxygen species 
act as a second messenger and can for example inactivate certain phosphatases. 
The regulation mechanism is often due to the oxidation and reduction of certain 
cysteine residues, causing transient inactivation or activation of proteins. This type 
of reaction is called a redox reaction and involves the transfer of electrons between 
two compounds. In a redox reaction one molecule loses electrons and become 
oxidized while the other molecule gain electrons and is thereby reduced. In an 
oxidizing environment, thiol-groups are often reversibly modified to inter- or 
intradisulfide bond (-SS-) or a sulfenic (-SOH) acid [8]. 
 
Redox homeostasis is the balance between oxidants and antioxidants [6]. An 
imbalance between oxidants and antioxidants is called oxidative stress. Certain 
exogenous toxic agents, for instance different quinones, can cause increased 
amounts of oxygen radicals via redox cycling. Redox cycling reactions are self-
perpetuating coupled reactions that many times can lead to the generation of ROS. 
In the presence of transition metal ions, both superoxide radicals and hydrogen 
peroxide can form the highly reactive and aggressive hydroxyl radicals (OH•) [6]. 
 
Hydrogen peroxide can undergo the Fenton reaction:  
 
Fe2++H2O2→Fe3++OH−+OH• 
 
and together with superoxide  
 
Fe3+(Cu2+)+O2•
-→Fe2+(Cu+)+O2 
 
the Haber-Weiss reaction (the net reaction) 
 
O2•
-+H2O2→OH•+OH-+O2 
 
Too high levels of ROS can cause oxidative damage towards cellular compounds 
such as proteins, nucleic acids, and lipid membranes. Furthermore, breakdown 
products produced during lipid peroxidation can cause further damage to the cell 
[21]. The breakdown products are often aldehydes, such as malonaldehyde and 4-
hydroxy-2-nonenal (4-HNE), which among other things can covalently modify 
proteins. Under conditions of oxidative stress superoxide radicals can directly react 
with nitric oxide (an important signaling molecule of several physiological 
processes e.g. involved in the cardiovascular system) to form peroxynitrite 
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(OONO-). Peroxinitrite is a highly reactive oxidant involved in protein nitration, 
which can also convert into other toxic species (OH• and NO2) [22]. The degree of 
intracellular oxidative stress will result in different cellular outcomes and too high 
levels of ROS can lead to cell death. The amount of ROS will also determine how 
the cell will undergo cell death, since several of the proteins involved in the cell 
death machinery are redox sensitive, for example proteases belonging to the 
caspase family [23,24]. 
 
1.3 CANCER AND OXIDATIVE STRESS 
Increased levels of ROS have been implicated in age-associated diseases such as 
neurodegenerative diseases, atherosclerosis and cancer [9,10,25]. ROS can 
stimulate cell proliferation and motility, and promote tumor formation and 
progression [9,26,27,28]. For instance, ROS can inactivate the function of the 
phosphatase and tensin homolog (PTEN), a known tumor suppressor gene. The 
inactivation of PTEN effects downstream events and ultimately promotes cellular 
growth, survival and metabolism [29]. Increased levels of ROS can also induce 
DNA damage and might cause genomic instability. Enhanced production of 
cellular ROS can be detected in many cancer cells, and to balance the increased 
levels of ROS tumor cells very often increase their expression of antioxidant 
enzymes [30]. The balance between oxidants and antioxidants appears to be more 
fragile in cancer cells than in normal cells. Chemotherapy mediated increases of 
intracellular ROS levels could therefore be a general mechanism in several cases of 
anticancer therapy.  
 
1.3.1 Nrf2 regulation of antioxidants 
Many of the proteins that are studied in this thesis show increased gene expression 
after exposure to oxidative or xenobiotic stress [15,31]. These proteins have 
antioxidant response element (ARE)-bearing genes that are regulated via the 
Keap1-Nrf2-ARE signaling pathway. Under non-stressed conditions the 
transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) is negatively 
regulated by kelch-like ECH-associated protein 1 (Keap1), promoting ubiquitin-
mediated proteasomal degradation of Nrf2. Keap1 works as an oxidative stress 
sensor, containing redox sensitive cysteine residues. Changes in the cellular redox 
homeostasis cause modifications of Keap1 cysteine residues, disrupting the 
association between Nrf2 and Keap1. Upon release, Nrf2 translocates to the 
nuclear space and activates ARE-responsive genes. The induction of Nrf2 target 
gene protects cells against genotoxic damage and cancer initiation [32,33]. 
However, once a cell has transformed, the Nrf2 activation will rather be an 
advantage for the cancer cell as this promotes cell proliferation and survival. A 
high constitutive expression of Nrf2 has for instance been found in certain forms of 
lung cancer [34,35]. 
 
Examples of Nrf2 target genes described in this thesis are: γ-glutamylcysteine 
synthetase (γ-GCS), γ-glutamyl transferase (γGGT), glutathione peroxidise 2 
(GPx2), glutathione S-transferases (GSTs), glutathione reductase (GR), 
peroxiredoxin 1 (Prx1), thioredoxin reductase 1 (TrxR1), thioredoxin 1 (Trx1) and 
the cystine/glutamate exchange transporter (xCT) [36,37,38,39,40]. Additionally, 
activation of Nrf2 has been shown to increase cellular NADPH production [41].  
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1.4 MAMMALIAN SELENOPROTEINS AT A GLANCE  
The Swedish chemist Jöns Jacob Berzelius, known as the founder of what would 
later become Karolinska Institutet, discovered the element selenium (Se) in 1817. 
In the beginning selenium was regarded as an environmental toxin, but during the 
1950s it was recognized as an essential trace element for mammals [42,43].  
 
Selenium is most commonly present in proteins in the form of selenocysteine 
(Sec), which is recognized as the 21st amino acid [44]. Random and non-specific 
selenium incorporation in the form of selenomethionine can also occur, but in this 
case the resulting proteins are not defined as selenoproteins [45]. Sec is a cysteine-
analogue (see Fig 1) where the sulfur atom is replaced by selenium, hence 
changing its chemical properties. Sec has, compared to cysteine, a stronger 
nucleophilicity and a lower pKa value (5.2 for the selenol versus 8.5 for the thiol), 
resulting in most of the Sec being in the deprotonated selenolate form at 
physiological pH [44]. 
 
 
Fig 1. The chemical structure of Cys and Sec. 
 
The number of selenoproteins varies across eukaryotes. Zebrafish, for instance, 
have 37 selenoproteins while the roundworm Caenorhabditis elegans has only 
one selenoprotein, an orthologue to TrxR1 [45,46]. In humans 25 different 
selenoprotein coding genes have been found, whereas rodents have 24 
recognized selenoproteins. Some organisms lack selenoproteins completely, for 
instance higher plants and fungal species. However, many of these species have 
Cys-containing counterparts instead.  
 
In proteins Sec is almost always placed in the active site of enzymes, serving 
catalytic functions [45,46]. Most of the characterized selenoproteins so far are 
oxidoreductases and have redox regulatory and protective functions in the cell. 
Mammalian selenoproteins can generally be divided into two groups based on the 
location of their Sec-residue. The first group has their Sec-residue close to their 
C-terminal end and includes proteins like TrxRs and methionine sulfoxide 
reductase 1B (MsrB1 or selenoprotein R). Msr is a protein involved in protein 
repair and protects cells against oxidative stress by taking care of oxidized 
methionine-residues. The second group of selenoproteins has their Sec-residue 
located in the N-terminal or center regions and includes, for instance, GPxs, 
iodothyronine deiodinase, and selenophosphate synthetase 2 (SPS2). Only one 
selenoprotein contains multiple Sec residues, selenoprotein P, hence it cannot be 
placed in any of the two groups. Selenoprotein P has one Sec, supposedly redox 
active, located in the N-terminal region of the proteins and nine additional Sec-
residues, which are located in the C-terminal domain. Selenoprotein P has a 
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important role in selenium transport and selenium homeostasis [47]. 
Selenoproteins, such as selenoprotein I, K, M, O, T have physiological functions 
which are still largely unknown. 
 
1.4.1 Biosynthesis of selenoproteins in eukaryotes 
Sec incorporation is encoded by a dedicated UGA codon, which otherwise 
usually specifies termination of protein synthesis. Various factors are required for 
the ribosomes not to recognize the Sec-encoding UGA as a stop codon, the 
selenocysteine insertion sequence (SECIS) element being one of these essential 
factors. The SECIS element is an mRNA secondary stem-loop structure normally 
located in the 3′ untranslated region (UTR) of the mRNA [48,49,50]. Its presence 
does not always lead to Sec incorporation and under certain conditions Cys can 
be incorporated instead [51,52,53]. This seems to be dependent on selenium 
availability since mice fed a selenium deficient diet showed incorporation of Cys 
instead of Sec into TrxR1 [52,53]. The complex needed for the translation and 
incorporation of Sec consists of the SECIS-binding protein 2 (SBP2), which is 
associated to the elongation factor EFSec and the Sec specific tRNA, SECp43, 
and the ribosomal protein L30. SBP2 have different binding affinity towards 
various SECIS elements and can thereby to some extent regulate the production 
and the amounts of selenoproteins. Furthermore, increased levels of ROS have 
been shown to affect the SECIS affinity of SBP2 and result in decreased Sec 
incorporation [54].  
 
Sec synthesis is special, since it does not occur as a free amino acid in the cell. 
Instead Sec is synthesized directly onto the tRNA. Sec synthase (SecS) converts 
the phosphoseryl moiety of the tRNAsec into a selenocysteinyl group by using 
selenophosphate (SePO3), giving rise to Sec-tRNA
sec. The selenophosphate is 
produced via SPS2 from selenide (Se2-) and ATP. In vitro, SPS2 has also been 
shown to generate thiophosphate (SPO3) by using sulfide (S
2-) instead of selenide 
as a substrate. Though, SPS2 has a much lower substrate specificity towards 
sulfide compared to selenide. Thiophosphate can then potentially be used by 
SecS, hence leading to the formation of Cys-tRNAsec instead of Sec-tRNAsec 
[53].  
 
Selenide, in turn, originates from selenite (SeO3
2-), which can be reduced to 
selenide by either the thioredoxin system or glutathione [55,56]. Selenide is 
highly reactive and can easily oxidize into selenite again. TrxR1 is believed to be 
the major reductant of selenite in the mammalian system and should therefore be 
required for selenoprotein synthesis.  
 
1.4.2 Selenium nutrition in relation to health and cancer 
In nature, selenium is found in the -2 (selenide), 0 (selenium), +4 (selenite), and +6 
(selenate) oxidation states. The dose of 50% lethality (LD50) ranges between 1.5 
and 6 mg/kg for many selenium compounds and animal species [57]. Selenium is 
an essential micronutrient for humans and selenium deficiency is associated with a 
wide array of diseases including cancer, cardiovascular diseases, male reproductive 
problems and immune suppression [58,59]. In Sweden and US the recommended 
daily intake is between 70 and 55 µg Se. Supranutritional selenium 
supplementation (~ 200 µg Se/day) has been recognized as cancer preventive, 
though only individuals with low baseline levels of selenium may show reduced 
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cancer incidence [60,61,62]. The beneficial affects of selenium likely arise from 
both low molecular weight selenium compounds and selenoproteins [63]. There 
has also been conflicting data reported concerning selenium supplementation and 
cancer prevention, which reflects the complexity of the roles of selenium in human 
health [62]. There is an ongoing discussion arguing that it is not only the amount of 
selenium intake that is important, but also its form. Furthermore, the level of 
selenium intake varies substantially between individuals due to dietary reasons. For 
example, selenium levels in food vary due to geographical location [64,65]. The 
role of selenium in the biology of human health is still far from fully understood 
and will continue to be an interesting area of research. 
 
1.5 ANTIOXIDANTS 
Antioxidants regulate the cellular redox environment and protect cells against 
oxygen-induced toxicity. Cellular antioxidants are often divided into two groups, 
enzymatic and low molecular weight antioxidants [6].  
 
1.5.1 Low molecular weight antioxidants 
Ascorbate (vitamin C) is water-soluble antioxidant scavenging radicals such as 
superoxide- (O2•
-), hydroxyl- (OH•), alkoxyl (RO•) peroxyl- (ROO•), urate (UH•-) 
and tocopheryl-radicals (TO•) [6]. The tocopheryl radical is reduced by the 
ascorbate to tocopherol (vitamin E) generating an ascorbyl radical instead. Two 
ascorbyl radicals can then spontaneously react with each other, forming an 
ascorbic acid and a dehydroascorbic acid, thereby acting as a radical chain-breaker. 
α-Tocopherol is the most potent and biologically active form of the tocopherols. It 
is a lipid-soluble antioxidant that can quench free radicals by becoming a stable 
radical itself, the tocopheryl-radical, and is thereby protecting the integrity of lipid 
membranes. Other examples of low molecular weight antioxidants are: R-α-Lipoic 
acid (thioctic acid), a sulfur-containing antioxidant and enzyme cofactor, and 
glutathione (GSH), which will be further described in the next section.  
 
Consumption of food and beverages rich in flavonoids and polyphenols is 
associated with a reduced risk of age-associated diseases [66,67,68]. Several 
naturally occurring flavonoids and phenolic compounds have been shown to 
possess antioxidant and anti-inflammatory properties, having chemopreventive- 
and chemotherapeutic functions. Their abilities as antioxidants include chelating 
transition metals and scavenging radicals. Their direct cellular antioxidant 
functions have however been challenged by data showing that polyphenols under 
certain conditions can act as pro-oxidants [67,69]. A number of flavonoids can 
form semiquinone- and quinone like metabolites which potentially can redox cycle 
in the cell and lead to ROS formation. It is suggested that their pro-oxidant action 
as modifiers of signal transduction pathway is responsible for attributed health 
beneficial effects. Several of these phenolic chemopreventive compounds have for 
instance been identified to induce the Nrf2 pathway [32].  
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1.5.2 Antioxidant enzymes 
The glutathione (GSH) system together with the thioredoxin (Trx) system are 
considered to be the major antioxidant and redox regulatory enzyme systems in the 
mammalian cells. The list of cellular redox-regulatory enzymes is long and also 
includes enzymes such as the mitochondrial and cytosolic superoxide dismutases 
(MnSOD and Cu/ZnSOD), important for catalyzing the dismutation of superoxide, 
producing hydrogen peroxide and oxygen [70]. Other important enzymes are 
peroxiredoxins (Prx) and catalase, abundant proteins catalyzing the conversion of 
hydrogen peroxide to water and oxygen [6,71].  
 
Because the GSH and Trx system are central to this thesis, especially in relation to 
cancer therapy, these aspects shall be discussed in further detail.  
 
1.6 RIBONUCLEOTIDE REDUCTASE 
Ribonucleotide reductase (RNR) catalyzes the rate-limiting step in de novo 
synthesis of 2'-deoxyribonucleotides (dNTPs) from the corresponding 
ribonucleotides. RNR thereby provides the pool of deoxyribonucleotides required 
for DNA replication and repair [72,73]. The activity of RNR, as well as its 
substrate specificity, is highly regulated via allosteric interactions. Besides the 
salvage pathway of nucleotides, RNR is the only enzyme known to produce 
dNTPs. RNR is a complex of two dimeric proteins (R1 and R2) and its activity is 
mostly restricted to the S-phase (synthesis phase), making it a well-suited target for 
the development of anticancer and antiviral agents. Electrons for the catalytic 
activity of RNR are provided via the Glutaredoxin (Grx) and Trx system 
respectively [74,75,76]. Trx and the GSH-dependent electron donor Grx were 
originally discovered in different strains of Escherichia coli (E.coli) due to their 
ability to serve as cofactors for for RNR [74,76].  
 
1.7 THE GLUTATHIONE SYSTEM 
GSH is a major intracellular antioxidant present in millimolar concentration (0.5-
10 mM) [11,77]. GSH is nucleophilic and can directly react with both electrophilic 
and oxidizing species, or by itself to reduce substrates such as dehydroascorbate. It 
is also used as a cofactor by glutathione peroxidase (GPx), glutaredoxin (Grx) and 
glutathione S-transferase (GST) (see Fig 2). Glutathione reductase (GR) is 
responsible for keeping the cellular GSH pool in a reduced state. GR is a 
homodimeric flavoprotein and belongs to the family of pyridine nucleotide-
disulfide oxidoreductases, reducing the oxidized form of GSH, glutathione 
disulfide (GSSG), by transferring electrons from its cofactor nicotinamide adenine 
dinucleotide phosphate (NADPH) [78]. Levels of NADPH are maintained by the 
cytosolic enzyme glucose-6-phosphate dehydrogenase (G6PD) in the pentose 
mono phosphate pathway [79].  
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Fig 2. A schematic overview of the GSH system. GSH supports the functions of GPx, Grx and GST, thereby 
getting oxidized to GSSG. GSH can be regenerated from GSSG by GR using the reductant NADPH+H+. γ-GGT is 
the enzyme catalyzes the first step in GSH salvage pathway. γ-GGT may under certain circumstances metabolize 
certain GSH-conjugates to more reactive thiols, giving rise to very toxic metabolites. The principle steps of the 
GSH biosynthesis are also illustrated in the figure.  
 
 
1.7.1 GSH synthesis 
GSH (L-γ-glutamyl-L-cysteinyl-glycine) is a tripeptide comprised of glutamate 
(Glu), cysteine (Cys) and glycine (Gly). GSH is synthesized by γ-glutamylcysteine 
synthetase (γ-GCS) and GSH synthetase (GS), where γ-GCS catalyzes the rate-
limiting step in de novo biosynthesis of GSH. The availability of cysteine is often 
the limiting and critical factor for the GSH biosynthesis. Cysteine used for the 
GSH synthesis is for instance provided via the cystine/glutamate exchange 
transporters (xCT). xCT facilitates the uptake of cystine (Cys-S-S-Cys), which is 
reduced to cysteine inside the cell, either by the Trx-system or by GSH [36].  
 
1.7.2 GPx 
Glutathione peroxidases (GPxs) were the first mammalian proteins discovered to 
be selenoproteins [43]. Today five selenium-containing GPxs have been identified 
in humans (GPx1-4 and 6) and the various isoforms of GPx differ in their cellular 
localization and substrate specificity [80]. GPx protect the cells against oxidative 
damage by catalyzing the reduction of H2O2, organic hydroperoxides and lipid 
hydroperoxides.  
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1.7.3 Grx 
The two major forms of Grx in mammals are Grx1 and Grx2 (additionally there 
are two monothiol forms; Grx3 and Grx5) [81]. Upon reduction of substrates, the 
active site dithiol of Grx gets oxidized, but can be reactivated and reduced by two 
molecules of GSH. Grx can reduce substrates either by a dithiol or by monothiol 
mechanism. The monothiol mechanism involves in this case the formation and 
reduction of protein-GSH mixed disulfides. The reduction of protein-GSH mixed 
disulfides (deglutathionylation) is often the favored monothiol reaction. Proteins 
have been shown to be glutathionylated during conditions such as oxidative stress, 
thus protection and redox regulation could potentially also occur via protein s-
glutathionylation [82]. It should be noted that the importance of glutathionylation 
and its mechanism is still largely unknown. Grx1 contains the active site Cys-Pro-
Tyr-Cys and is mainly located in the cytosol. Grx1 acts as a hydrogen donor for 
RNR and has been shown to redox regulate transcription factors such as nuclear 
factor κB (NF-κB) [83]. Grx2 is localized to the mitochondria and contains the 
active site Cys-Ser-Tyr-Cys. Grx2 can catalyze deglutathionylation of 
mitochondrial proteins, and one of its suggested targets is mitochondrial complex I. 
Interestingly, oxidized Grx2 is not exclusively reduced by GSH but also by 
thioredoxin reductase (TrxR) [84]. 
 
1.7.4 GSTs 
Mammalian GSTs are a multi gene family of phase II detoxification enzymes that 
can be divided into three principle groups, cytosolic, mitochondrial and 
microsomal GSTs. [85,86]. GSTs catalyse the conjugation of GSH to a large 
variety of endogenous and exogenous electrophilc compounds, and the addition of 
GSH usually results in less reactive and more water-soluble compounds. 
Subsequently GSH conjugates are exported from the cell by multiple drug 
resistance associated proteins (MRPs or ATP-binding cassette transporters C). 
There are some cases where the conjugation of GSH can lead to the formation of 
metabolites that are more reactive than the parent compound [77,87,88]. γ-GGT is 
catalyzing for the first step in the GSH salvage pathway and can potentially 
metabolize extracellular GSH-conjugates to more potent and toxic products. γ-
GGT is situated on the extracellular cell-surface and normally hydrolysis the γ-
glutamyl bond between glutamate and cysteine in excreted GSH. The cleaved 
glutamate can be transported back into the cell, often after conjugated to an amino 
acid. The cysteinylglycine is then cleaved by a membrane dipeptidase, generating 
cysteine and glycine, which also can be taken up by different amino acid 
transporters and be re-used by the cell. 
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1.8 THE THIOREDOXIN SYSTEM  
The thioredoxin (Trx) system, consisting of thioredoxin, thioredoxin reductase 
(TrxR) and the cofactor NADPH, is a ubiquitously expressed redox regulatory 
system. The active site disulfide in oxidized Trx is reduced and thereby reactivated 
via TrxR, using NADPH as the electron donor [89]. The Trx system has a diverse 
set of functions in the cell (see Fig 3), which are described in further detail below.  
1.8.1 The different forms of mammalian Trx and TrxR 
There are two different major forms of Trx in mammals. Trx1 is predominantly 
found in the cytoplasm and in the nuclei, whereas Trx2 is localized in the 
mitochondria. Trx1, and a truncated form of Trx1 (Trx80), can also be found 
extracellularly carrying out immunomodulatory functions [90,91]. The 
homozygous Txn1 and Txn2 knockout mice both show early embryonic lethality 
[92,93], whereas mice with overexpressed Trx1 showed greater resistance towards 
oxidative stress [94].  
 
There are three different isoforms of mammalian TrxR; cytosolic TrxR1 [89], 
mitochondrial TrxR2 [95], and thioredoxin glutathione reductase (TGR) mainly 
expressed in testis [96]. The homozygous mouse knockouts of Txnrd1 and Txnrd2 
are both embryonically lethal [97,98,99]. Two different Txnrd1 knockout mice 
have been described in the literature, and interestingly these knockouts show 
somewhat different time-points for embryonic death. With the mouse strain 
published by Jakupoglu et al, where only the last exon of the Txnrd1 gene was 
removed, death occurred between embryonic day (ED) 8.5 and 10.5. In contrast, 
the mouse strain published by Schmidt et al, where exons 1 and 2 were deleted, 
showed embryonic lethality slightly earlier (ED 8.5). The slight difference in 
lethality between these two strains has a major functional impact, since in the latter 
strain no mesoderm was formed, whereas it was formed in the strain published by 
Jakupoglu et al. The molecular explanation for these differences is still unknown. 
Different tissue specific Txnrd1 knockouts have also been established and have 
recently been reviewed [100]. Knockout mice with a nervous-system specific 
deletion of the Txnrd1 gene experienced ataxia and tremor, and showed incomplete 
developed of cerebellum [101]. However, the mice with a neuron specific Txnrd1 
gene deletion did not show any phenotype. Moreover, untreated knockouts with 
either a heart- or hepatocyte specific Txnrd1 gene deletion showed no obvious 
phenotype [98,102,103]. Txnrd1 deficient hepatocytes showed induced Nrf2-
dependent gene transcription, which could be seen as a form of compensatory 
response potentially explaining the lack of phenotype after gene deletion.  
 
1.8.2 The Trx system in relation to cancer 
Both Trx and TrxR have been shown to be up-regulated in a large number of tumor 
cells [104]. In addition, increased expression of Trx1 has been associated with 
more aggressive tumors and decreased patient survival [104,105,106]. Rapid 
proliferation and cell growth, with accompanying increased ROS production, is 
one of the main characteristics of cancer. Inhibition of cellular antioxidant systems 
in cancer can thereby cause massive accumulation of ROS due to the higher basal 
ROS output in these cells. The Trx system plays a central role in 
deoxyribonucleotide production and cellular redox regulation, as described above. 
Hence, targeted inhibition of the Trx system could have a crucial effect on cell 
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viability or increase the sensitivity of the tumor cells towards other 
chemotherapeutic agents. Several of the anticancer drugs available today indeed 
target the Trx-system. The Trx-system has therefore been proposed to be a 
potential and promising target for anticancer therapy [107]. 
 
It has been implicated that TrxR1 has a role in cancer prevention, but its functions 
in this context are complex and under certain conditions it seems to take part in 
promoting cancer [59,108]. The role of TrxR1 in cancer development clearly needs 
to be further elucidated. Previous results from mice injected with siRNA-mediated 
TrxR1 knockdown lung carcinoma cancer cells showed that TrxR1 was required to 
sustain tumorigenic properties [109]. On the other hand, in a different tumor mouse 
model system where tumor cells had a genetic deletion of the Txnrd1 gene, the 
expression of TrxR1 was not required for the tumorgenesis [110]. These studies 
further illustrate the complexity at play. Some other important factors in need of 
consideration are base line levels of selenium and TrxR activity levels, effects of 
TrxR depletion on compensatory systems and of course other genetic differences.  
 
1.8.3 Trx  
Trx is a small (∼12 kDa) and globular disulfide reductase with a conserved Cys-
Gly-Pro-Cys active site, present throughout all kingdoms of life [111]. Besides 
providing RNR with reducing equivalents, Trx1 catalyzes the reduction of 
peroxiredoxins (Prx) [71] and methionine sulfoxide reductase (Msr) [112]. 
Reduced Trx1 has also been shown to block the degradation of I-κB in the cytosol, 
preventing nuclear translocation of NF-κB. In the nuclear compartment, Trx1 
affects the function of several transcription factors, by reducing critical cysteine 
residues. The regulation either occurs directly, reducing the transcription factor 
NF-κB for example [113,114,115], or indirectly via redox factor-1 (APE/Ref-1), 
which can reduce activator protein 1 (AP-1) and HIF1α [116,117]. In addition, the 
total protein levels of HIF1α also seem to be affected by the Trx1 activity [118]. 
Examples of in vitro non-protein substrates of Trx1 are GSSG, insulin and H2O2 
[119,120]. In Drosophila melanogaster, all GSSG is reduced not by GR but by Trx 
and it is thus possible that a similar Trx-dependent backup system for GSSG 
reduction exists also in mammalian cells [121].  
 
Trx may also act as a molecular switch, activating/inactivating target protein and 
thus down-stream signaling events. The reduced form of Trx1 can noncovalently 
interact with apoptosis signal-regulating kinase (ASK1) [122] and PTEN and thus 
acts a negative regulator [123]. The association is redox dependent and upon 
oxidation of Trx the complexes are dissociated. Trx1 can also interact with the 
thioredoxin binding protein 2 (TBP2), which as been identified as a negative 
regulator of Trx1 [124].  
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Fig 3. Schematic illustration of the Trx system and its principal cellular functions. The Trx-system acts as 
an electron donor for e.g. Prx, RNR, and Msr proteins. Trx also act as a redox dependent molecular switch, 
regulating the activity of target proteins such as ASK1 and PTEN. Trx is kept in a reduced state via TrxR, using 
NADPH as a source of electrons. TrxR may also reduce several other cellular targets, both other proteins, e.g. 
TRP14, and low-molecular weight compounds such as lipoic acid and dehydroascorbate.  
 
1.8.3.1 The Trx system in relation to p53 activity 
p53 is a transcription factor regulating genes involved in cell cycle arrest, DNA-
repair, senescence and cell death [125]. Due to its major regulatory impact on cell 
fate, the expression and activity of p53 in the cell is tightly regulated. p53 is redox 
regulated and the activities of antioxidant systems, such as the Trx system, have 
been linked to p53 functions. One study showed for instance that the deletion of 
the yeast orthologue of TrxR1 (Trr1) significantly impaired p53 activity [126]. 
Additionally, inhibition and modification of TrxR1 by lipid electrophiles in a 
mammalian cancer cell line caused conformational changes to p53 and impaired its 
function [127]. The cancer cells depleted of their TrxR1 were however less 
sensitive towards the electrophile-induced disruption of p53 [128]. Some of these 
results could partly be linked to the oxidation status and function of Trx. The DNA 
binding affinity of p53 is regulated via APE/Ref-1, which in turn needs to be 
reduced by Trx [129].  
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1.8.4 TrxR  
TrxR is a homodimeric flavoprotein (FAD) (∼ 110 kDa) belonging to the family of 
pyridine nucletide-disulfide oxidoreductases [130,131]. Mammalian TrxR was 
originally purified from bovine and rat [89,119] and recognized to be a 
selenoprotein by Stadtman in 1995 [132,133,134]. The structure and the first part 
of the enzymatic reaction of mammalian TrxR is highly similar to GR, TrxR does 
however carry an extra 16 amino acid long C-terminal tail [135]. This C-terminal 
tail is flexible and includes the Sec-containing redox active motif, Gly-Cys-Sec-
Gly, conserved in all mammalian TrxRs.  
 
Comparing the human TXNRD1 gene with its mouse orthologue renders a 
conserved genomic organization and their cDNA sequences share ∼ 80% 
homology [131,135]. TrxRs between higher and lower organisms, for instance in 
bacteria, yeast and plants differ substantially. The TrxRs in lower organisms are 
smaller (the dimer is ∼70 kDa) and their substrate spectrum is narrower. The small 
form of TrxR1 also lack the Sec-residue and instead has a redox active dithiol 
[136].  
 
1.8.4.1 Transcriptional regulation of TrxR1 expression  
The transcriptional regulation of the mammalian gene encoding TrxR1 is very 
complex and involves alternative promoters and extensive alternative splicing 
[135,137,138]. The core-promoter of the gene has no TATA box, but instead 
DNA-binding sites for Oct-1, Sp1 and Sp3. Upstream of the core promoter there is 
a Nrf2 ARE binding motif and in the 3′UTR, downstream of SECIS, there are AU-
rich elements. AU-rich elements are mRNA sequence elements rich in adenosine 
and uridine bases, mediating recognition of RNA binding proteins. These proteins 
can regulate splicing, stability or translation of mRNAs. AU-rich elements are 
generally found in transiently expressed genes, such as different transcription 
factors. The gene for TrxR1 contains 7 AU-rich motifs and deletion of these 
generally result in stabilization of the mRNA [139]. The mRNA binding and 
regulating proteins which have been shown to bind to the mRNA of TrxR1 are 
human antigen R (HuR) and tristetraprolin (TTP) [140,141]. 
 
1.8.4.2 Catalytic function 
Mammalian TrxR is generally described as a dimeric enzyme arranged in a head to 
tail direction with active sites located in the N- and C-terminals (see Fig 4). The 
catalytic mechanism has been thoroughly studied and described [130,142,143,144]. 
The completely oxidized form of TrxR1 (Eox) is in the first round reduced by one 
equivalent of NADPH. The FAD will accept the electrons, giving rise to a two 
electron reduced flavine (FADH2). The N-terminal active site contains a redox 
active dithiol motif, Cys-Val-Asn-Val-Gly-Cys, to which the FAD will donate the 
electrons. One of electrons is transfered to Cys 59 and a charge-transfer complex is 
created between the FAD and Cys 64 (EH2). This charge-transfer complex (EH2) 
can be detected spectrophotometrically at a wavelength of 540 nm. The N-terminal 
redox motif of one subunit will subsequently shuttle the electrons to the C-terminal 
active site of the other subunit, giving rise to the selenolthiol. Upon reduction with 
a second equivalent of NADPH, a new thiolate-FAD charge-transfer complex can 
be formed, thus resulting in a four electron reduced enzyme species (EH4). The 
four electron reduced enzyme species is believed to be the major form catalyzing 
substrate reduction. Reduction of Trx is mediated via the C-terminal selenolthiol 
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motif (of EH4), giving rise to the two electron reduced enzyme with the thiolate-
FAD charge-transfer complex (EH2) and a selenenylsulfide. Upon reduction with 
another equivalent of NADPH, the four electron reduced enzyme can be recycled 
and reduce the next substrate. Important to note is that TrxR1 also has a Sec-
independent inherent superoxide producing NADPH oxidase activity [145]. 
 
Fig 4. Overview of TrxR1 homodimer. The two enzyme subunits are arranged in a head-to-tail orientation where 
each subunit consists of three domains. TrxR1 has a dithiol (Cys 59 and Cys 64) catalytic motif in the N-terminal 
and the main catalytic motif located in the C-terminal and containing a selenolthiol (Cys 497 and Sec 498).  
 
 
 
1.8.4.3 Substrates of TrxR 
With the Sec residue being surface exposed and very reactive, TrxR1 has broad 
substrate specificity. Beside Trx, which is regarded as the major cellular substrate, 
TrxR1 can reduce a number of low molecular weight compounds such as selenite 
[146] and methylseleninate [56], DTNB (5,5′-Dithio-bis(2-nitrobenzoic acid) 
[147], lipid hydrogen peroxides [148], lipoic acid [149], dehydroascorbate 
[150,151] and menadione (vitamin K3) [89]. Other protein substrates of TrxR1 are 
thioredoxin-related protein 14 (TRP14) [152,153], glutaredoxin 2 (Grx2) [84] and 
endoplasmic reticulum (ER) binding protein disulfide isomerase (PDI) [131].  
 
1.8.4.4 TrxR inhibitors  
Oxidized enzyme species, containing the selenenylsulfide bond between the C-
terminal Cys and Sec is very resistant to modifications by eletrophilic agents. The 
C-terminal selenolate is however very susceptible and easily targeted by 
eletrophilic compounds. Irreversible Sec-derivatized TrxR1 enzyme species are no 
longer capable of reducing Trx or any other substrate requiring an intact C-
terminus. Many inhibitors of TrxR1 have been published over the years and some 
of these are also clinically used [107,131,154,155]. Examples of typical TrxR 
inhibitors include: gold compounds (auranofin and aurothioglucose) used in the 
treatment of rheumatoid arthritis, ifosfamid [156,157], arsenic trioxide [158], 
platinum compounds [159] and nitrogen mustards (chlorambucil, melphalan) 
[160], which are all used in chemotherapy. Several naturally occurring agents, such 
as 4-HNE [161], different flavonoides [162,163] and isothiocyanates [162] are also 
efficient inhibitors of TrxR1. Some inhibitors, such as DNCB (1-chloro-2, 4-
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dinitrobenzene) [163], curcurmin [164] and juglone (5-hydroxy-1,4-
naphthoquinone) [165], efficiently bind to and inhibit the C-terminal Sec of TrxR1 
while also being capable of promoting maintained redox cycling with the inhibited 
enzyme and NADPH. The compounds can hence get reduced via FAD/ N-terminal 
dithiol-motif, strongly inducing the NADPH oxidase activity of TrxR1 and 
therefore converting the protein into a pro-oxidant ROS producer [166]. It is worth 
noting that the previously mentioned TrxR inhibitors, arsenic trioxide and 
auranofin, also have been shown to block general selenoprotein synthesis [167]. 
Electrophilic compounds utilized in the different papers included in this thesis are 
summarized in table I.  
 
 
 
 
 
 
Fig 5. Schematic illustration of TrxR1 inhibition by electrophilic compounds. Many electrophilic drugs can 
specifically and irreversibly targeted the Sec-residue located in C-terminal active site, responsible for the reduction 
of Trx. Alternatively, both active sites can be targeted by electrophilic agents. If only the C-terminal motif is 
modified by the electrophilic agent and the N-terminal redox active motif remains intact, the NADPH-oxidase 
activity of the enzyme may become induced, hence giving rise to pro-oxidant enzyme species. 
 
 
1.8.4.4.1 Cisplatin and other platinum drugs in relation to Trx system 
cDDP was first synthesized by Peyrone in 1845, and its function as an inhibitor of 
cell division was discovered by Rosenberg in 1965 (see Fig 6) [168]. cDDP has 
been clinically used for more than 30 years and several different platinum 
compounds have been synthesized since then. Oxaliplatin (Oxa) (see fig 6) and 
carboplatin (cis-diammine-1,1-cyclobutane- dicarboxylatoplatinum(II)) are two 
other platinum anticancer drugs which are in clinical use today [169].  
The molecular mechanism of cDDP was originally attributed to its ability to 
crosslink DNA. More recently, cDDP has been shown to cause extensive oxidative 
and nitrosative stress, which has a significant impact on its cytotoxicity [170]. 
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cDDP and Oxa have been shown to efficiently inhibit TrxR1 in vitro [159,160]. 
Carboplatin, in contrast, could not inhibit the enzyme in vitro. cDDP is a platinum 
compound with two amine groups and two chlorides in the cis-orientation and 
upon administration cDDP undergoes non-enzymatic hydrolysis whereby the 
chlorine atoms bound to the platinum are replaced by water. The hydrolysed 
species are suggested to be the major cytotoxic forms [171,172]. cDDP is used to 
treat non-small cell lung cancer as well as bladder, ovary, testis, head and neck 
cancers. However, side effects such as renal insufficiency and ototoxicity limit the 
use. Increased ROS production is believed to play a central role in both cDDP-
derived nephrotoxicity and ototoxcity [170,173]. cDDP accumulates rapidly in the 
kidneys cortex and mice treated with cDDP showed significant inhibition of TrxR 
[174,175]. The principle site of cDDP-derived toxicity in kidneys is the proximal 
straight tubule. In cochlea, the cDDP targets outer hair cells in the basal turn of the 
organ of Corti, cells of the stria vascularis and the spriral ganglion neurons [173]. 
cDDP and carboplatin have similar clinical profile but carboplatin is more stable 
and causes less severe side effects [176]. Oxa has another clinical profile and is 
used for treatment of colon cancer. Kidney and ototoxicity are both less common 
side effects of Oxa treatment.  
 
 
 
 
Fig 6. Structural Illustration of the platinum drugs cDDP and Oxa. 
 
 
Increased expression and activity of Trx have been shown to correlate with 
increased cellular cDDP resistance and could therefore be a contributing factor 
[177,178]. In agreement with this, down-regulation of Trx by RNA interference 
enhanced cDDP-induced cytotoxicity [179]. Increased expression of TrxR1 does 
not necessarily cause protection and cellular resistance towards cDDP. Previously 
published results show that cDDP-derivatized TrxR1 species gain a new pro-
oxidant function, capable of inducing cell death. cDDP-derivatized TrxR1 species 
have been named: selenium compromised thioredoxin reductase derived apoptotic 
proteins (SecTRAPs). SecTRAPs have a non-functional C-terminal active site, 
while the redox-function in FAD/ N-terminal dithiol-motif is maintained, thereby 
still having NADPH oxidase activity. The truncated form of TrxR1, lacking the 
last two amino acids (Sec-Gly), has been shown to have a similar activity [166]. 
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Table I. Chemicals used in papers I-VI 
 
Chemical Effects on TrxR Paper 
Cisplatin (cDDP)  
 
Inhibitor of TrxR and can generate 
SecTRAPs  
Crosslinks DNA and proteins. Increases 
cellular ROS levels 
I, IV, VI 
Oxaliplatin (Oxa) Inhibitor of TrxR 
Forms DNA adducts 
I, IV 
DNCB (CDNB)  
 
Inhibitor of TrxR and causes increased 
superoxide generating NADPH-oxidase 
activity 
I 
Auranofin Inhibitor of TrxR 
Inhibits overall selenoprotein synthesis 
I, II 
Juglone 
5-Hydroxy-1,4-naphthoquinone 
Inhibitor of TrxR and causes increased 
superoxide generating NADPH-oxidase 
activity 
I 
Menadione 
2-Methyl-1,4-naphthoquinone, Vitamin K
3
 
Substrate of TrxR  
Can redox-cycle and causes oxidative 
stress and depletion of cellular GSH 
I 
Resveratrol 
3,5,4'-trihydroxy-trans-stilbene 
Weak inhibitor of TrxR. Activates Sirt1 
activity 
III 
RITA (NSC 652287) 
2,5-bis(5-hydroxymethyl-2-thienyl)Furan 
Reversible inhibitor of TrxR. Targets p53 
and prevent its interaction with Mdm2 
II 
 
 
 
  18 
 
 
  19 
2 AIMS OF THIS THESIS 
The main aim of this thesis was to investigate the potential importance of TrxR1 as 
a target for anticancer therapy and its possible association with therapy related 
adverse side effects.  
 
Specific objectives in papers I-VI were to:  
• Explore the function and implications of high TrxR1 expression in 
cancer cells. 
 
• Assess the molecular mechanism of TrxR inhibition by RITA. 
 
• Investigate the molecular mechanism behind resveratrol-mediated 
inhibition of neural differentiation of neural stem cells (NSC) as well as 
to study the potential effects of wine and resveratrol on NSC and 
cancer cell survival. 
 
• Elucidate pharmacokinetics and ototoxicity profile differences between 
the two platinum anticancer drugs cDDP and Oxa. 
 
• Elucidate the role and importance of the two different electron donor 
systems based upon Trx and GSH for replicative potential in 
hepatocytes, thus de novo synthesis of dNTPs by RNR. 
 
• Investigate whether targeting of TrxR1 by cDDP in kidneys is 
significant for the cDDP-induced adverse nephrotoxicity.  
 
  20 
 
 
  21 
3 PRESENT INVESTIGATION 
3.1 METHODOLOGY 
Here follows a brief introduction to some of the methods used in paper I-VI. For 
more detailed information, see Materials and methods sections for each paper.  
 
3.1.1 Cell cultures 
For most cell-culture experiments described in papers I-IV, commercially available 
human cancer cell lines were used. The most frequently used cell lines were A549 
lung carcinoma cells, colon cancer HCT116 cells, HCT116 TP53-/- cells and 
neuroblastoma SH-SY5Y cells. Additionally, fibroblasts were used for 
experiments in paper II, and in paper III a major part of the experiments were 
performed using primary embryonic neural stem cells (NSCs) isolated from rat.  
 
3.1.2 RNA silencing 
In papers I-III, a widely applied RNA interference technique to induce silencing of 
gene expression was used [180]. Short double-stranded RNA molecules, 21 
nucleotides long and referred to as small interference RNA or siRNA, were 
introduced by a transient delivering system. siRNA can induce a sequence-specific 
degradation of homologous mRNA sequences, subsequently causing a down-
regulation of protein levels. However, the technique rarely results in a complete 
knockdown of target genes and there is a risk of off-target effects.  
 
3.1.3 75Se radioisotope labeling  
75Se-labeling is a convenient and sensitive method for detecting Sec-incorporation 
into proteins. The method is very specific and only proteins having the UGA-
codon together with a SECIS element will be radioactively labeled. This method 
was applied in paper I to determine the degree of siRNA-mediated knockdown of 
TrxR1 protein levels in cell cultures, by growing A549 cells in the presence of 
75Se-labeled selenite.  
 
3.1.4 Measuring ROS 
In papers II and III two different probes were used for detecting possible induction 
of ROS levels in cell cultures.  
• 2,7-Dichlorodihydrofluorescein diacetate (DCF-DA) – mainly used as an 
indicator of peroxynitrite anions (ONOO-). Upon oxidation, the fluorescent 
molecule DCF is formed (paper II). 
• Dihydroethidium – mainly used as a superoxide-indicator. Upon oxidation, 
ethidium is formed which can intercalate with DNA, resulting in a red 
fluorescent nucleus (paper III).  
The specificity of these probes has been discussed quite extensively [181]. 
Questions such as sensitivity, marker specificity and probe-product reactivity 
should be considered carefully and taken into evaluation. Samples were analyzed 
by fluorescence-activated cell sorting (FACS). 
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3.1.5 Cell proliferation and viability assays 
Depending on the material and desired readout, exposure to drugs was evaluated 
differently in papers I-VI. An overview to the methods used in papers I-VI is 
presented in table II. Samples were analyzed using normal light or fluorescence 
microscopy and for some of the applications, analyses were performed using 
FACS or a custom modified automated microscope system.  
 
 
Table II. Methods applied to assess cell viability and growth. 
 
Method Staining mechanism Paper 
SubG1 
Propidium iodide (PI) 
Stains DNA and can be used to distinguish necrotic 
and apoptotic cells from each other. Can also be 
used for DNA content in cell cycle analysis. 
I, II 
Vital Dye Assay based on plasma membrane integrity, a 
mixture of dyes detecting live and dead cells. 
Analyses were automated. 
I 
Annexin V 
Fluorescently labeled with FITC 
Annexin V is a protein preferentially binding to 
Phospahtidylserin and thereby stains apoptotic 
cells. 
III 
DAPI 
Hoechst 33342 
Stains DNA of living and dying cells. Detecting 
morphological changes. 
III 
Apoptosens Measuring DEVDase activity by detecting caspase-
cleaved keratin 18. 
IV 
anti-PCNA 
Proliferating cell nuclear antigen 
Antibody detecting PCNA, synthesized mainly in 
G1 and S phase. 
V 
anti-PHH3 
Phosphorylated histone H3 
Antibody detecting PHH3, a marker for late G2 and 
M phase. 
V 
anti-BrdU  
5-bromo-2’-deoxy-uridine 
BrdU can be incorporated into DNA, which then 
can be detected with an antibody towards BrdU. 
V 
TUNEL Catalytic incorporation of fluorescein-12-dUTP at 
3’-OH DNA ends. 
VI 
H&E  
Hematoxyline & eosin 
 
Hematoxylin is a basic dye staining the nuclei. 
Eosin is a acid dye staining the cytoplasm. 
VI 
   
3.1.6 Measuring enzyme activity  
3.1.6.1 Trx and TrxR activity assay  
Enzyme activity assays were performed on cell- or tissue lysates in paper I-VI. To 
measure total activity of Trx or TrxR, a previously developed endpoint insulin 
assay was applied [147]. The assay can be used for determination of either Trx or 
TrxR activity, using a relative excess of one of the proteins. The assay is based 
upon the fact that Trx is rapidly oxidized by insulin and TrxRs are the only 
enzymes known to reduce Trx. Appropriate amounts of samples were incubated at 
37°C with NADPH, excess amounts of insulin and recombinant human Trx1 or rat 
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TrxR1. To stop the enzymatic reaction, a high concentration guanidine 
hydrochloride (GuHCl) solution is added to the reaction mixture. The GuHCl 
solution also contains DTNB, hence the number TNB anions formed will reflect 
the number of Trx-dependent insulin thiols in the reaction. The activity is 
determined by spectrophotometric measurements at 412 nm (TNB ε =13.600 M-1 
cm-1). A background absorbance reference was included for each sample. It should 
be noted that with the herein described standard assay it is not possible to 
distinguish between TrxR1 and TrxR2, and the activity is therefore always referred 
to as total TrxR activity.  
 
3.1.6.2 GR and GST activity assay 
Glutathione reductase (GR) activity was measured by detecting the NADPH-
dependent reduction of oxidized glutathione (GSSG) at 340 nm (NADPH ε =6200 
M-1 cm-1) in paper I [182]. Glutathione S-transferase (GST) activity was measured 
in paper VI using DNCB, which is a substrate for a broad range of GSTs. GST 
catalyze the conjugation of GSH to DNCB, the product formation can then be 
monitored as a change in absorbance at 340 nm [183,184].  
 
3.1.6.3 GSH depletion and total GSH+GSSG levels determination 
L-Buthionine-SR-sulphoximine (BSO) is a potent inhibitor of γ-GCS and thereby 
inhibits the GSH synthesis and was therefore used to deplete cellular levels of 
GSH in papers I and V. Total levels of GSH, not distinguishing between the 
reduced and oxidized form, was quantified according to the GR-DTNB recycling 
assay [185].  
 
3.1.6.4 Recombinant protein assay 
Standard in vitro assays with recombinant rat TrxR1 enzyme, used in paper II and 
III, were the DTNB (5,5´-dithio-bis(2-nitrobenzoic acid)) assay and the insulin-
coupled Trx assay [147]. DTNB is a direct substrate of TrxR, which is reduced to 
two TNB anions and can be detected at 412 nm. DTNB can be reduced both at the 
C-terminal active site (95% of the substrate molecules) and to a small part also via 
the FAD/N-terminal dithiol-motif (5%). In the Trx assay, the NADPH 
consumption is detected at 340 nm and the assay reflects possible changes, e.g. 
inhibition, to both TrxR and Trx. The Trx is only reduced through the C-terminal 
active site of TrxR. 
 
3.1.7 Guinea pig model for inner ear studies 
A guinea pig model was used to study differences between cDDP and Oxa in 
pharmacokinetics and cochlear hair cell toxicity in paper IV. This system is a well-
established model for studying cochlear effects of ototoxic drugs since structure 
and hearing range of the guinea pig ear is similar to that of humans [186].  
 
3.1.8 The Cre/LoxP recombination systems  
Homozygous inactivation of the Txnrd1 gene results in embryonic lethality. 
However, the Cre/LoxP inducible site-specific recombination technology makes it 
possible to circumvent this problem and assess the Txnrd1 gene function in adult 
mice. The Cre/LoxP system enables site-specific DNA recombination of LoxP 
flanked chromosomal DNA sequences [187]. With the Cre/LoxP technology it is 
therefore possible to generate tissue-specific knockouts and it also allows geneti
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disruption of the target gene under specific conditions. Hence, in paper V and VI 
an already established conditional Txnrd1 knockout mouse model was used 
[99,102,103]. The conditional Txnrd1 knockout mice are born as functional wild 
type animals. It is first upon the expression of Cre recombinase as the first two 
exons from the Txnrd1 gene are excised [99]. The first two exons of the Txnrd1 
gene are placed between two LoxP sites (see fig 7). mRNA is still issued from the 
Txnrd1 null allele, but these mRNA molecules are not engaged by ribosomes and 
will therefore not be translated. Furthermore, to be able to distinguish cells with 
active Cre, the Txnrd1 conditional knockout mice also have a two-color Cre-
responsive reporter gene (ROSAmT-mG) (see fig 7) [188]. Accordingly, generated 
Txnrd1 null cells will turn green-fluorescent while cells without conversion remain 
red-fluorescent. It should here be noted that the intracellular protein status of Cre-
targeted cells will also depend upon the half-life of TrxR1 and the fluorescent 
proteins. 
 
Fig 7. Schematic illustration of Cre recombination of the ROSAmT-mG allele and Txnrd1 conditional allele. 
The β-actin enhancer enhances expression of the ROSA26 promotor, driving strong expression of a membrane-
targeted version of the tdTomato (mT). The ROSAmT-mG mouse have Cre reconizeble loxP sites on both sides of 
the mT cassette and upon Cre expression the mT cassette is deleted, allowing expression of membrane tagged 
GFP instead. Concerning the Txnrd1 conditional allele, the Cre excises exons I and II, including the ATG start 
codon and the N-terminal redox-motif 
 
Mice with a hepatocyte specific Cre expression were used in paper V to knockout 
Txnrd1. The Cre expression is here under the control of the albumin promoter 
(AlbCre), consequently giving a hepatocyte specific gene inactivation [189]. A 
tissue specific knockdown may be preferable to complete knockouts, since total 
knockout of a gene could be embryonic lethal or lead to a very complex phenotype 
and thereby making results difficult to interpret. The negative aspect is however 
having a constantly active Cre, which potentially can have affects on cellular 
function. In paper VI, mice ubiquitously expressing an inducible form of Cre in all 
tissues were also used. The Cre gene has in this case been fused to a mutant form 
of the ligand binding domain of the estrogen receptor (CreER) [190]. Hence the 
mutant receptor binds tamoxifen or 4-hydroxytamoxifen (4-OHT), but not 
estradiol. In its inactive form, CreER is retained in the cytosol, but when CreER 
binds 4-OHT, CreER translocates to the nucleus. The activation of Cre will give 
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rise to cell-specific deletion of genes, creating a mosaic mouse having both Txnrd1 
null and non-converted Txnrd1-containing cells in all tissues. An advantage with 
CreER mice is the inducibility of Cre recombination expressed in all tissues. On 
the other hand, depending on local concentrations of 4-OHT, the conversion 
efficiency could differ substantially between animals, as well as between different 
tissues in a single animal. Furthermore, the 4-OHT exposure can in itself 
potentially have effects on the animal. The different mouse models used in paper V 
and VI are summarized in table III. 
 
Table III. Txnrd1 status in liver and kidney of the different mouse models used in paper V and VI. 
 
Txnrd1 status 
Mouse strain Liver Kidney 
C57BL/6J wild types +/+ +/+ 
Mosaics after 4-OHT 
Txnrd1 cond/cond 
+/+ and -/- +/+ and -/- 
AlbCre controls +/+ +/+ 
Txnrd1 cond/null AlbCre -/- +/- 
Txnrd1 cond/+ AlbCre +/- +/+ 
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3.2 RESULTS AND CONCLUSIONS  
3.2.1 Paper I 
Eriksson SE, Prast-Nielsen S, Flaberg E, Szekely L, Arnér ES. High levels of 
thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy.  
 
The Trx-system has been shown to be over-expressed in many tumors and cancer 
cell lines [104,191]. Hence, the aim of this study was to further investigate the role 
of high TrxR1 expression in cancer cells. To study this, siRNA was utilized to 
transiently down-regulate the levels of TrxR1 in a human lung cancer cell line 
(A549), which is known to express very high levels of both TrxR1 and Trx1 
(www.proteinatlas.org). A549 cells have previously been shown to harbor a 
mutation in the Keap1 gene, leading to a constitutive activation of the Nrf2 
pathway, which might explaining the high expression levels of TrxR and Trx [35].  
 
In this study it was found that down-regulation of TrxR1 levels to ~ 10% of the 
original levels had no apparent effect on the cell growth or on cell cycle 
distribution. Even if the TrxR1 deficient A549 cells were subjected to GSH 
depletion there was hardly any effect on the cell viability or on the cell growth 
after 72 h. By growing cells in the presence of BSO, the total cellular GSH+GSSG 
pool was decreased by 98 %. The lack of distinct phenotypic effects after 
knockdown, with and without GSH depletion, indicated that the remaining TrxR 
activity was enough to sustain the activity of Trx, and subsequently for example 
support DNA synthesis. The TrxR activity remaining in TrxR1 siRNA-mediated 
knockdown cells were in the same range as the activity in measured tissue extracts 
from normal mouse liver or kidney (see paper V and VI).  
 
The TrxR1 activity originally measured in the A549 cells, grown in the presence of 
25 nM selenite, was substantially higher than the measured Trx activity, suggesting 
that TrxR1 might have other cellular functions as well, or (less likely) not being 
used at all. Furthermore, it was investigated whether A549 cells, after transiently 
lowering the levels of TrxR1, showed different toxicity profiles towards a set of 
compounds typical known to interact or target TrxR1. The resulting drug 
sensitivity assays showed a multifaceted picture. A549 cells with the endogenous 
high expression of TrxR1 were less sensitive towards DNCB and menadione 
compared to the siRNA treated cells. There was however no difference in 
sensitivity detected towards auranofin or juglone. Interestingly, cells with high 
expression of TrxR1 were more sensitive towards cDDP. The increased sensitivity 
towards cDDP-derived damage in cells overexpressing TrxR1 can be explained by 
earlier published data, which shows that cDDP derivatized TrxR1 protein species 
can gain a new and pro-oxidant function in a cellular system [166]. 
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3.2.2 Paper II 
Hedström E, Eriksson S, Zawacka-Pankau J, Arnér ES, Selivanova G. p53-
dependent inhibition of TrxR1 contributes to the tumor-specific induction of 
apoptosis by RITA.  
 
Inactivation of p53 is one of the most frequent alterations in a tumor cell 
[192,193]. This can be achieved either by direct mutation of the TP53 gene or via 
the up-regulation of its negative regulators. p53 is a key regulator of cell fate upon 
cellular damage. The p53 pathway is therefore seen as a prime target in the 
development of new chemotherapeutic drugs. Pharmacological approaches of 
reactivating the tumor suppressor functions of wild-type p53 could be a very 
efficient and valuable strategy in anticancer therapy [194]. Several p53-targeting 
low molecular weight compounds have been shown to efficiently inhibit tumor 
growth. RITA (reactivation of p53 and induction of tumor cell apoptosis, NSC 
652287) is one example of such a compound, proposed to bind to the N-terminal 
domain of p53, thereby blocking interactions with its negative regulators, such as 
the ubiquitin ligase Mdm2 [195]. p53 is a redox regulated transcription factor, 
hence several connections have been made between the Trx-system and 
p53 [127,129,196]. In the light of these earlier findings, the aim of paper II was to 
further explore the molecular mechanism of RITA and investigate if TrxR1 could 
be an additional target of RITA.  
 
In this study, it was shown that RITA binds non-covalently to TrxR1 and inhibits 
its activity in vitro. Even more interesting was that HCT116 tumor cells exposed to 
RITA showed, together with a reduced cellular TrxR activity, induced formation of 
a stable high molecular weight form of TrxR1. This high molecular form of TrxR1 
was detected upon immunoblotting and was not observed upon exposure to 
auranofin, which is a very efficient inhibitor of TrxR. It was also seen that siRNA-
mediated knockdown of TrxR1 eliminated the high molecular weight TrxR1 form. 
Mass spectrometry (MS) analysis confirmed that the high molecular form of 
TrxR1 was a covalently linked dimer. The TrxR1-dimer was also 75Se-labeled. 
Nevertheless, the covalently linked dimer could not be detected in vitro, using 
incubation of RITA with purified recombinant TrxR1. However, it has been 
proposed that RITA could become metabolized to more reactive species, which are 
capable of binding covalently to different cellular targets. The metabolism of RITA 
into more reactive metabolites can thus be one explanation to why the dimer of 
TrxR1 was not formed upon incubation in vitro with intact RITA [197].   
 
Furthermore, cells treated with RITA showed induced cellular ROS levels, which 
were correlating with the formation of the TrxR1-dimer and the subsequent 
induction of cell death. The increased ROS production was also p53-dependent. 
HCT116 TP53-/- cells exposed to RITA showed no increase in ROS production, 
less TrxR inhibition, and had only minor amounts of the TrxR1-dimer as compared 
to the HCT116 wild type cells. Cells exposed to auranofin also showed increased 
ROS production and cell death, although the effects could not be correlated to 
covalently linked TrxR1-dimer. Additionally, fibroblasts treated with RITA 
showed increased total TrxR activity and there was no increase in ROS production.  
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3.2.3 Paper III 
Wallenborg K, Vlachos P, Eriksson S, Huijbregts L, Arnér ES, Joseph B, 
Hermanson O. Red wine triggers cell death and thioredoxin reductase inhibition: 
effects beyond resveratrol and SIRT1.  
 
Moderate consumption of red wine has long been postulated to have positive 
health effects [198]. Red wine contains a cocktail of polyphenols and many of 
these have antioxidant properties [68]. Resveratrol is one of these polyphenols and 
several studies have speculated that resveratrol could be responsible for some (or 
most) of the beneficial health effects of red wine. Resveratrol has for example been 
suggested to be a cancer chemopreventive agent. The aims of paper III were to 
investigate potential effects of wine and resveratrol on neural stem cells (NSC) and 
cancer cell survival. Furthermore, it was assessed whether resveratrol-mediated 
effects on NSC and cancer cells were dependent on SIRT1 activity. SIRT1 is a 
NAD+-dependent class III histone deacetylase, important for many cellular 
processes including gene silencing, regulation of p53 and NF-κB activity [199]. It 
was discovered that low concentrations (0.5-3 µM) of resveratrol inhibited neural 
but not astroglia differentiation of NSC via a SIRT1-dependent mechanism. These 
results indicate that SIRT1 could act as a repressor of neural differentiation.  
 
Resveratrol at higher concentrations (≥10 µM), however, induced NSC and 
neuroblastoma cell death independent of the cellular SIRT1 status. Furthermore, 
NSC and various cancer cell lines exposed to red wine (1-5 % v/v) showed a rapid 
onset of cell death. White wine on the other hand, at the same concentrations, had 
no effects on the cell viability. This red wine-induced cell death was also shown to 
be independent of ethanol, SIRT1 and resveratrol and was instead associated with 
increased oxidative stress and inhibition of cellular TrxR activity.  
 
Inhibition studies using recombinant TrxR1 showed that the inhibition potential of 
red wine could be correlated to the increase in absorbance at 520 nm, and therefore 
linked to the color compounds in wine. Incubating recombinant TrxR1 with 
resveratrol resulted in a weak enzyme inhibition (< 20%) and no inhibition was 
detected in a cellular system. Wine is a complex mixture of many different 
substances, for instance polyphenols, such as resveratrol and tannins, and 
flavonoids, such as quercetin, myricetin and anthocyanins, several being important 
for giving wine its color. Many of these compounds are mainly found in the skin of 
grapes, depending on the vinification process and the grapes used, the 
concentration of these will therefore vary. Two flavonoids which can be found in 
wine, quercetin and myricetin, are known to irreversibly inhibit TrxR1 [200]. Red 
wine dependent inhibition of TrxR is however most likely an additive effect of 
several molecules.  
 
Although red wine as such is unlikely to reach TrxR1 in cancer cells, this study 
showed that i) red wine contains substances other then resveratrol that have strong 
effects on cells, and ii) some of those compounds are efficient inhibitors of TrxR1. 
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3.2.4 Paper IV 
Hellberg V, Wallin I, Eriksson S, Hernlund E, Jerremalm E, Berndtsson M, 
Eksborg S, Arnér ES, Shoshan M, Ehrsson H, Laurell G. Cisplatin and oxaliplatin 
toxicity: importance of cochlear kinetics as a determinant for ototoxicity.  
 
Ototoxicity is a dose-limiting side effect of cDDP treatment. cDDP targets all sub-
regions of the cochlea and the cDDP-induced hearing loss is usually irreversible 
[201]. Oxa is another platinum compound used in chemotherapy, which has a 
different clinical profile and ototoxic side effects are rarely observed. Both 
compounds have previously been shown to inhibit TrxR1 in vitro, and Oxa was 
shown to be the most efficient inhibitor of TrxR1 [159]. The aims of paper IV were 
to elucidate the differences in toxicity profile and pharmacokinetics between these 
two platinum anticancer drugs. It was discovered that the cochlear uptake of Oxa 
was lower than for cDDP, this being most likely the main explanatory factor to 
why Oxa does not cause ototoxicity to the same extent as cDDP. Inner ear studies 
were performed in guinea pigs, which were also shown to express TrxR1 in the 
organ of Corti.  
 
cDDP and Oxa showed similar levels of apoptosis induction in HCT116 cells. Pre-
treatment of cells with a superoxide scavenger (Tiron), or a calcium chelator 
(BAPTA-AM), reduced the cDDP-induced apoptosis while pre-incubation with 
Tiron or BAPTA-AM had no effect on Oxa-induced apoptosis. Furthermore, 
HCT116 cells incubated with 20 µM cDDP showed inhibition of total TrxR 
activity, which was not seen after similar treatment with Oxa in the HCT116 cells. 
Hence, cDDP and Oxa induce cell death through different pathways. cDDP 
treatment causes increased levels of ROS and induced cell death, which is partly 
nucleus-independent. Since the hair cells in cochlea are terminally differentiated, 
DNA independent derived toxicity may perhaps be more crucial.  
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3.2.5 Paper V 
Prigge JR, Eriksson S, Iverson SV, Meade TA, Capecchi MR, Arnér ES, Schmidt 
EE. Hepatocyte DNA replication in growing liver requires either glutathione or a 
single allele of Txnrd1.  
 
RNR sustains the cellular homoeostasis of nucleotides by catalyzing the rate-
limiting de novo synthesis of 2'-deoxyribonucleotides (dNTP) from the 
corresponding ribonucleotides [72,73]. The redox active cysteine residues in RNR 
can be reduced by either Grx or Trx [74,75,76]. Previous studies have shown that 
Txnrd1 null/null hepatocytes can replicate normally [103]. Hence, the aims of this 
study were to explore the role of the two different electron donor systems, Grx and 
Trx, for hepatocyte replicative potential and thus de novo synthesis of dNTPs by 
RNR.  
 
The mitochondrial TrxR2 has also been shown to catalyze the reduction of 
cytosolic Trx1. Therefore it was previously proposed that there could be different 
splice forms of TrxR2 in the cytosol, potentially capable of supplying reducing 
equivalents to Trx1 [202]. It was therefore investigated whether these potential 
cytosolic mRNA forms of TrxR2 exist in mammalian hepatocytes. To approach 
these questions inducible Cre/loxP mediated tissue-specific hepatocyte Txnrd1-
knockouts were used.  
 
Results from this study show that Txnrd1 null/null livers had a ~75 % reduction in 
total TrxR activity as compared to wild types. The remaining TrxR activity most 
likely derives from TrxR2 and the non-hepatocytic cell fraction present in liver. 
There was virtually no expression of the TrxR2 mRNA cytosolic splice forms, 
neither in normal nor in Txnrd1 null/null livers, suggesting that TrxR2 is unlikely 
to compensate for the loss of TrxR1 in this system. Furthermore, wild type mice or 
mice heterozygous for the Txnrd1 gene, subjected to GSH depletion by BSO 
treatment, showed no effect on hepatocyte replication index. The replicative 
potential was only affected in Txnrd1 null/null lives of mice treated with BSO, 
which show a significant decrease in replication. These results show that the Trx-
system and GSH-system act in a complementary fashion, and can independently 
from each other support hepatocyte proliferation by delivering electrons to RNR. 
The requirement of nucleotides varies between different cell types, and the 
accessibility of reducing equivalents from either the GSH or Trx system might also 
differ depending on the cellular situation or on the cell type. This is the first 
mammalian in vivo model studying the role of the two different RNR electron 
providers in relation to DNA replicative potential in hepatocytes.  
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3.2.6 Paper VI 
Eriksson S, Iverson SV, Prigge JR, Capecchi MR, Arnér ES, Schmidt EE. 
Thioredoxin reductase 1 status in liver and kidney influences the extent of 
nephrotoxicity triggered by cisplatin. Manuscript.  
 
cDDP is a widely used anticancer drug displaying nephrotoxicity as a major dose-
limiting side effect. The mechanism of cDDP-derived nephrotoxicity is not yet 
entirely understood and damage is primarily located to the proximal tubule cells. 
However, oxidative stress has been shown to be an important factor for the derived 
toxicity [170,203]. TrxR1 is a known cDDP-target, thus the aim of the present 
study was to investigate whether the targeting of TrxR1 by cDDP in kidneys is 
significant for cDDP-induced adverse effects. To evaluate this hypothesis 
inducible Cre/loxP mediated conditional Txnrd1 knockout mice were used.  
 
The cDDP-induced kidney toxicity was first studied the in a 4-OHT induced 
CreER mosaic mice, having both Txnrd1 null and wild type Txnrd1 containing 
cells in all tissues. Secondly, to investigate whether changes in liver xenobiotic 
metabolism, as a result of TrxR1 deficiency and Nrf2-activation [102], could affect 
the outcome of cDDP-derived nephrotoxicity, AlbCre hepatocyte-specific Txnrd1 
knockout mice were used. Both mosaics and tissue-specific Txnrd1 knockouts 
express a two color Cre-responsive reporter gene (ROSAmT-mG).  
 
Animals were intraperitoneal injected with either cDDP or saline. Hepatocyte-
specific Txnrd1 knockout mice and the AlbCre control mice had a significantly 
higher TrxR1 activity in kidney compared to both mosaics and wild type animals. 
AlbCre animals showed in general more cDDP-induced kidney damage as 
compared to wild type controls. There seems to be a difference in cDDP-induced 
pathology between the different mouse models, which most likely can be explained 
by the TrxR1-status in the kidneys. Mosaic mice were also more susceptible 
towards cDDP-induced nephrotoxicity as compared to wild types. Interestingly 
TrxR enzyme activity in total kidney was not altered between mosaics and wild 
types. Results showed, however, that mosaic animals had reduced levels of TrxR 
activity in the liver as compared to wild types, which could be correlated to the 
degree of kidney injury. The results from immunohistochemistry on kidney using a 
TrxR1 antibody revealed that mosaics, compared to wild type animals, had a more 
heterogeneous expression pattern of TrxR1. Thus the Txnrd1 genetic conversion in 
mosaic kidneys seems to have given null cells in parallel with compensatory 
increased levels of TrxR1 in other cells, and the compensatory effect was even 
more apparent after cDDP treatment. Results presented in manuscript VI reveals a 
complex mechanism and the major conclusions drawn from the current data 
suggests that a Txnrd1 genetic deficiency in liver together with high expression 
levels of TrxR1 in kidney increase the susceptibility to cDDP-induced kidney 
damage.  
 
Yet, to be truly able to draw conclusion from the data presented, there is a need to 
further assess and validate the data. There are a number of confounding factors that 
need to be further evaluated: 
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• The selenium status in mice. There is significant difference in the total 
TrxR activity in kidney between the wild types and AlbCre control 
animals. Differences in dietary selenium status could be one plausible 
explanation to variations in enzyme activity [52].  
• Gender differences. To correct for this factor several animals will be 
needed in future experiments [204,205]. 
• Potential limitations in the Cre-mediated gene inactivation approach. 
Possible adverse effects from the 4-OHT administrations and the potential 
impact of the Cre-expression per se needs to be ruled out [190,206]. 
Furthermore, to be able to draw conclusions from the kidney histology of the 
mosaic model, there is a need to securely identify what cell types that are 
converted as well as being damaged by the cDDP-treatment the existing 
mosaic models. 
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4 DISCUSSION AND FUTURE PERSPECTIVE  
The main objective of this thesis was to explore the role of TrxR1 as a drug target and 
its significance for chemotherapy derived side effects. The effect of TrxR1 targeting 
was shown to be drug-specific and dependent on the cellular levels of TrxR1.  
 
In paper I, the effects of siRNA-mediated TrxR1 knockdown in a cancer cell line 
(A549), normally overexpressing TrxR1, was investigated. The TrxR1-deficient cancer 
cells showed no effects on cell growth or viability and they were shown to be 
insensitive to GSH depletion. The total TrxR activity remaining in the deficient cells 
was ∼ 10% of that found in the control cells. Protein analysis by MS indicated that most 
of the remaining TrxR activity in TrxR1-deficient cells was due to TrxR1, and not 
because of TrxR2 as originally thought. Hypothetical calculations, as to the DNA 
synthesis potential, imply that the activity still remaining in TrxR1-deficient cells 
would be enough reducing power to sustain the Trx-related functions in the cell. 
Results from in vivo experiments presented in paper V support this notion. In this paper 
it was shown that the total TrxR activity measured in the extracts from wild type mice 
was comparable to the total activity measured in TrxR1-deficient cancer cells.  
 
In addition, it was also shown that siRNA-mediated TrxR1 knockdown in cancer cells 
caused increased sensitivity towards the typical oxidative stress inducing agents 
menadione and DNCB. Interestingly, the TrxR1 deficient cells were found to be more 
resistant towards cDDP treatment. These results go well together with previously 
reported data, which show that cDDP alkylated TrxR1 potentially can gain a new and 
pro-oxidant function in cancer cells (SecTRAP) [166]. cDDP treatment could also 
result in covalently linked complexes of TrxR together with either Trx or TRP14 [207]. 
These complexes were also recently detected in kidney and liver extracts from cDDP 
treated mice (unpublished results). The mechanism for producing the complexes and 
their potentially cellular function is currently under investigation. Furthermore, recent 
experiments from our lab, with recombinantly produced proteins, show that the Sec to 
Cys mutant of TrxR1 is not as easily inhibited by cDDP. In cell culture experiments, 
were the formation of the Sec to Cys variant of TrxR1 was induced by growing cells in 
the presence of thiophosphate, the cytotoxicity towards cDDP was reduced (submitted 
manuscript Peng et al).  
 
As described above, the A549 cancer cell line used in paper I had ∼ 10 times more 
TrxR activity as compared to normal liver or kidney, hence these cells seem to have 
large overcapacity and the function of overexpressed TrxR1 protein has not been fully 
elucidated. Is the sole effect of the extra enzyme species to serve as a backup or are 
there other dedicated substrates in need of reducing equivalents? TrxR1 has been 
shown to have broad substrate specificity in vitro, reducing not only Trx, but also other 
proteins and low molecular weight substances. TRP14 is a quite recently discovered 
protein shown to be a substrate of TrxR1 and the functions of this protein are still 
largely unknown [152,153,208]. Recent unpublished results from our group show that 
the efficiency of TRP14 reduction by TrxR1 is similar to the activity with Trx. These 
results however need to be confirmed, enzymatic properties of TRP14 are currently 
being characterized. TrxR has also been implicated to play a role in mammalian 
selenium metabolism by reducing different selenium species into selenide (Se2-), which 
subsequently can be used for selenophosphate synthesis [56,209]. To further study the 
role of TrxR1 in selenium metabolism and homeostasis, the different Txnrd1 knockout 
mouse models utilized in papers V and VI could become valuable tools.  
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In paper II it was demonstrated that RITA could cause increased levels of ROS and 
inhibition of TrxR activity, in a p53-dependent manner. In vitro, RITA was found to be 
a reversible inhibitor of TrxR1. Nonetheless, RITA treatment of cancer cells gave a 
covalently linked TrxR1-dimer. It has been suggested that RITA is metabolized to more 
reactive species capable of covalently linking different cellular targets, hence 
potentially explaining this phenomenon [197,210]. The dimerization however, seems to 
only occur with a fraction of the cellular TrxR1 protein, correlating with the RITA-
induced ROS production. The dimerization could be a result of increased ROS levels 
confined to specific subcellular areas, where ROS directly or indirectly might effect the 
function of TrxR1 [20,211]. We recently discovered that RITA induced apoptosis as 
well as the covalent TrxR1 dimerization, could be prevented by pre-incubating cells 
with nordihydroguaiaretic acid (NDGA). NDGA is a lipoxygenase inhibitor having 
ROS scavenging capacity [212]. Ongoing studies are aiming to elucidate the 
mechanism behind the covalent TrxR1-dimerization.  
 
In paper III it was shown that red wine but not white wine could inhibit the TrxR 
activity, both in vitro and in cell cultures. Red wine contains a complex mixture of 
polyphenols and flavonoids, many of these could potentially affect the function of 
TrxR. Isolating naturally occurring inhibitors could be a beneficial strategy to find new 
drug candidates, which potentially would possess less toxic side effects. However, 
fractionation and identification of different phenolic compounds and flavonoids in red 
wine is a time-consuming and difficult task. A more efficient alternative to characterize 
new candidates of TrxR1 inhibitors and substrates, is to use small molecule libraries for 
high-throughput biochemical drug-screenings [213].  
 
Cochlea and kidney related side effects from cDDP treatment have been linked to 
increased ROS production [173,201,214]. Thus, the aims of papers IV and VI were to 
explore the pharmacological targeting of TrxR1 by cDDP and its potential role in 
adverse side effects. In paper IV it was shown that cDDP, but not Oxa, induced cell 
death that involved increased ROS production, which should be of major importance 
for inducing damage in terminally differentiated cells, such as cochlear hair cells. Most 
importantly, it was here shown that the cochlear uptake of Oxa compared to cDDP was 
lower, likely explaining why Oxa only rarely cause hearing loss. Results showed that 
TrxR1 is expressed in cochlea, however, the potential correlation to degree of cDDP-
induced damage has not yet been evaluated. The mosaic mouse models, having both 
Txnrd1-deficient and Txnrd1-containing cells in all tissues, could potentially be utilized 
for evaluating the significance of TrxR1 in cochlea. Studying ototoxcicty in mice could 
become technically challenging due to their fast metabolic rate, making them less 
sensitive towards the cDDP-derived ototoxic side effects, and their small size [186].  
 
cDDP treatment has previously been shown to affect the TrxR activity in kidney and to 
be associated to the degree of damage [156]. In paper VI it was shown that the 
expression level of TrxR1 affected the degree of cDDP-induced renal damage. The 
degree of damage appeared not only to be dependent on the TrxR status in kidney, but 
also on the status in liver, making the output data rather complex and challenging to 
interpret. At this point, further analyses and more control experiments are still required 
to securely interpret the data and to identify the mechanism. cDDP treatment is 
suggested to primarily damage proximal tubule cells, thus it could be of interest to 
generate a proximal tubule specific Txnrd1 knockout, and there are already several 
mouse strains with kidney specific expression of Cre established [215].  
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In paper V it was shown that either the GSH-system or the TrxR1-dependent pathway, 
independently of each other, were able to support proliferation of hepatocytes. 
Furthermore, having only one functional Txnrd1 allele was still sufficient to sustaining 
the proliferation. Only livers from Txnrd1 null animals treated with BSO showed 
reduced DNA replication and none of these animals showed any signs of general effect 
on cell survival. Previous results from animals with Txnrd1 null livers showed chronic 
transcriptional induction of Nrf2 regulated genes [102]. Elevated Nrf2 transcriptional 
activity has also been described for γ-GCS knockout mice, while GSH-depletion in 
itself does not trigger Nrf2 activation [216,217]. The redox state of Trx has not been 
evaluated in the Txnrd1 null livers and since TrxRs are so far the only enzymes known 
to reduce Trx, evaluating the redox state of Trx could potentially be of high interest. 
Previous results from cancer cells with a transient siRNA mediated knockdown of 
TrxR1, showed no changes to cellular Trx redox state [218]. However, these cells also 
had a significant residual TrxR activity (see paper I), which could be enough for 
keeping Trx in a reduced state under non-stressing conditions. The mammalian Trx and 
GSH systems are clearly complementary to each other, but if and how they crosstalk in 
different mammalian cells and tissues has not been completely elucidated and will take 
much effort to fully characterize.  
 
The requirement for producing DNA precursors varies depending on cell type. 
Additionally, increased levels of ROS have been shown to diminish cellular dNTP 
pools [219]. Induced dNTP production and oxidative stress is a common attribute of 
cancer cells. Simultaneous inhibition of two major antioxidant systems, the Trx- and 
the GSH-system, will disturb the cellular redox balance and impair the dNTP synthesis, 
and could be a efficient strategy for killing tumor cells. It was recently shown that 
Txnrd1 null tumor established in mice, were highly susceptible towards BSO treatment 
and the subsequent GSH depletion [110].  
 
TrxR1 appears to have an important role in preventing tumor development, but it seems 
to be a double-edged sword as it also has a role in promoting cancer under certain 
conditions. TrxR1 and Trx have both been shown to be highly expressed in tumors and 
have been proposed as promising targets for anticancer therapy. However, the targeting 
of TrxR1 could also be important for, and associated with, certain chemotherapy-
derived side effects. The picture gets even more complicated by TrxR1 having a 
number of splice variants with still unknown tissue distribution and functions. The role 
of TrxR1 in general and its importance in tumor cells is still far from being fully 
understood. The role and targeting of TrxR1 should therefore be further explored. 
Acquired knowledge could in the future form the basis for improved therapeutic 
function of anticancer therapy and decrease the risks for associated side effects. 
Based upon the results from the studies described in this thesis and the discussion 
above, the following experiments/studies could be a potential next step in order to 
improve understanding of the role(s) of TrxR in cancer therapy: 
 
 
• The highly interesting data collected and presented in paper VI promote further 
investigation of the role of TrxR1 in cDDP-derived toxicity. Generating 
proximal tubule specific knockouts of Txnrd1 would be a useful tool to study 
this. 
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• Determining the mechanism behind the RITA-induced covalently linked 
TrxR1-dimer and the cDDP-induced TrxR-TRP14/Trx complexes. MS-based 
techniques could be used to analyze the protein complexes and results could 
potentially provide clues about mechanism and function. Furthermore, 
radioactively labeled RITA could be used to investigate if RITA metabolites 
can potentially covalently link TrxR1.  
 
• The knockout mouse models with conditional expression of TrxR1 described in 
this thesis could form the basis for studying the role of TrxR1 during tumor 
initiation/formation and progression.  
 
• By utilizing the hepatocyte specific Txnrd1 knockout mouse, the functions of 
Trx system in relation to selenium metabolism (and selenium toxicity), could 
potentially be clarified. 
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